Apimeds Pharmaceuticals US, Inc
APUS
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.13M
Close$
$-0.56
162.5% downside
Current Fair Value
162.5% downsideOvervalued by 162.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.13 Million |
|---|---|
| Enterprise Value | $9.70 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.55 |
| Beta | -0.31 |
| Outstanding Shares | 15,513,389 |
Return
| Return on Equity | -32.14% |
|---|---|
| Return on Assets | -28.79% |
| Return on Invested Capital | -18.72% |
Valuation & Multiples
| P/E Ratio | -0.14 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | 0.11 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.41 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.98 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 26, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.12%▲ 3.76% |
|---|---|
| Total Invested | $802,954▲ 23.73% |
| Investors Holding | 6▼ 1.00% |
ESG Score
No data
About Apimeds Pharmaceuticals US, Inc
2 employees
CEO: Erik C. Emerson Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment ...